Testosterone cypionate: what the label approves, and what the clinics charge

What is testosterone cypionate?

Testosterone cypionate is a prescription injectable androgen: the oil-soluble cyclopentylpropionate ester of testosterone, dissolved in cottonseed oil and given as an intramuscular injection for testosterone replacement in men. Attaching the cypionate ester slows how fast the hormone leaves the injection site, which is what lets a single shot cover a dosing interval the FDA-approved label sets at 2 to 4 weeks. Testosterone cypionate, testosterone enanthate and testosterone propionate are three different esters of the same hormone, and the Depo-Testosterone label states directly that cypionate and propionate should not be used interchangeably because their durations of action differ.

Cypionate is a Schedule III controlled substance under the Controlled Substances Act, which is why no legitimate route to it skips a prescriber and why a prescription for it cannot be refilled indefinitely. Depo-Testosterone, the label read for this page, is FDA-approved under application 085635, approved July 25, 1979. Compounded testosterone preparations are mixed by a pharmacy rather than approved by the FDA and carry no registration trial of their own. What compounded actually means.

What the label approves it for, and the sentence printed underneath

The indication is narrow and it is worth reading in the label's own words rather than a clinic's summary of them. DEPO-Testosterone Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Two conditions are listed under it.

1. Indication 1Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy.
2. Indication 2Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.

Who the label says should not take it

5 contraindications, in the label's order.

• Known hypersensitivity to the drug
• Males with carcinoma of the breast
• Males with known or suspected carcinoma of the prostate gland
• Women who are pregnant
• Patients with serious cardiac, hepatic or renal disease

The label also sets a diagnostic gate before the first dose, in the dosage section rather than in fine print: Prior to initiating DEPO-Testosterone (testosterone cypionate), confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range. Two draws, both in the morning, on separate days. A single afternoon lab is not what that sentence describes, and the same two-draw standard is what most insurers ask for. How the diagnosis gate plays out with insurance.

One more thing this label does not have: a boxed warning. The secondary-exposure boxed warning men read about belongs to the topical gels, where the dosed skin can transfer testosterone to a partner or a child on contact. AndroGel 1.62% (testosterone gel) carries it under the heading WARNING: SECONDARY EXPOSURE TO TESTOSTERONE. An injection has no dosed skin to touch, so it carries no equivalent warning. The four testosterone labels compared side by side.

Schedule III, and what it does to a monthly subscription

The label says it in one line: DEPO-Testosterone Injection contains testosterone, a Schedule III controlled substance in the Controlled Substances Act. Most pages stop there, as though the schedule were trivia. It is the fact that shapes how buying TRT online actually works.

What follows from that is the thing men discover three months in. A testosterone prescription cannot be set to refill forever: it ends at 5 refills or 6 months, whichever lands first, so a prescriber has to write a new one at least twice a year. What the regulation forces is a new prescription, not a new consultation, so whether that comes with an actual re-evaluation is the clinic's choice rather than the law's. The subscription that bills your card every month is a separate object from the prescription that authorizes the refills, and the second one expires on a clock the first one knows nothing about. Every clinic operating in the United States sits under the same rule, so how a platform handles that six-month wall is a fair question to put to it before you sign up.

The schedule also explains why the cheap route is not the obvious one. Cypionate is not a new drug. The application behind Depo-Testosterone, abbreviated new drug application (anda) 085635, was approved on July 25, 1979. The drug is not what you are paying for. The prescriber, the labs and the legal chain of custody are. What that adds up to per month.

The dose range, converted into the unit clinics actually use

Here is a small mismatch that causes a large amount of confusion. The label writes its replacement dosing per injection: For replacement in the hypogonadal male, 50-400 mg should be administered every two to four weeks. Every clinic, every prescription label and every forum thread writes it per week. The two are never printed together, so a man comparing his own dose to the label has to do the conversion himself.

Both figures are ours, not the label's, and they are arithmetic rather than a recommendation. What they are useful for is checking a number a clinic has quoted you. A protocol at 200 mg a week delivers the same total milligrams as the top of the labelled range, though not on the interval the label gives. A protocol above that is above the range the label describes in total milligrams, and the person prescribing it should be able to say why.

The interval is the part worth pausing on. The label prescribes an injection every 2 to 4 weeks. Weekly and twice-weekly injection is standard practice in this category, and it is not the interval printed on this label. Nor is the route always the labelled one: DEPO-Testosterone Injection is for intramuscular use only. It should not be given intravenously. Intramuscular injections should be given deep in the gluteal muscle.Subcutaneous injection is widely used and is not what that sentence describes. Neither of those makes a protocol wrong. Both mean your clinic is exercising clinical judgement past the label, and you are entitled to hear it framed that way rather than as the manufacturer's instruction.

One more line from the same section, because it is the reason a pharmacy swap is not always neutral: Testosterone cypionate should not be used interchangeably with testosterone propionate because of differences in duration of action. If your platform declines to tell you which ester it ships, that sentence is why the question is not pedantic.

Monitoring: what the label asks for, and what it leaves out

The whole of what this label says about routine bloodwork is one sentence in the precautions: Hemoglobin and hematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long-term androgen administration. Serum cholesterol may increase during androgen therapy.

Read it for what is missing. There is no interval. There is no threshold. “Periodically” is the whole instruction, which means a clinic checking you once a year and a clinic checking you every three months are both consistent with this label, and neither can tell you it is following a schedule the label sets.

The guideline is more specific than the label here. The American Urological Association, Testosterone Deficiency guideline states, at Statement 11, that prior to offering testosterone therapy clinicians should measure hemoglobin and hematocrit and inform patients regarding the increased risk of polycythemia, and it grades that a strong recommendation. Statement 12 adds that PSA should be measured in men over 40 before therapy starts. Both of those are baseline tests, which means they happen before your first injection or they do not happen. A questionnaire and a card number is not that.

The label's cardiovascular language is worth quoting rather than summarising, because it is more equivocal than either side of this argument usually admits: Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. It also records postmarketing reports of venous thromboembolic events, and instructs that blood pressure be monitored periodically. The four labels compared, plus what the TRAVERSE trial found.

Fertility, and the reason some men are offered a different drug

This is the consequence worth understanding before the first injection, and the label states it with a hedge that has to travel with the fact: Oligospermia may occur after prolonged administration or excessive dosage. The mechanism section explains the route: At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).

Exogenous testosterone tells the pituitary that there is plenty already, and the signal that drives sperm production falls with it. The AUA is blunter about the decision that creates. Its guideline states that exogenous testosterone therapy should not be prescribed to men who are currently trying to conceive, and grades it a strong recommendation, and it separately asks that the long-term impact on spermatogenesis be discussed with any patient interested in future fertility.

Related

• Online TRT clinics, scored and graded the 5 platforms in the table above, ranked on care rather than price
• What TRT actually costs per month membership, medication and labs added up
• Cheapest online TRT sorted strictly by price
• Is TRT covered by insurance the two-morning-draw diagnosis gate, as a coverage problem
• Testosterone side effects, from the four FDA labels
• Enclomiphene, the fertility-sparing alternative